Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Repligen Corporation is a medical instruments & supplies business based in the US. Repligen Corporation shares (RGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Repligen Corporation employs 1,128 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$182.61|
|52-week range||$138.00 - $243.72|
|50-day moving average||$201.18|
|200-day moving average||$200.32|
|Wall St. target price||$238.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.80|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-8.56%|
|3 months (2021-04-30)||-13.75%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Valuing Repligen Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Repligen Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Repligen Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 134x. In other words, Repligen Corporation shares trade at around 134x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Repligen Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Repligen Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Repligen Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $165 million.
The EBITDA is a measure of a Repligen Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$508.5 million|
|Operating margin TTM||26.22%|
|Gross profit TTM||$210.4 million|
|Return on assets TTM||4.82%|
|Return on equity TTM||7.39%|
|Market capitalisation||$13.2 billion|
TTM: trailing 12 months
There are currently 1.6 million Repligen Corporation shares held short by investors – that's known as Repligen Corporation's "short interest". This figure is 6.5% down from 1.7 million last month.
There are a few different ways that this level of interest in shorting Repligen Corporation shares can be evaluated.
Repligen Corporation's "short interest ratio" (SIR) is the quantity of Repligen Corporation shares currently shorted divided by the average quantity of Repligen Corporation shares traded daily (recently around 347150.87336245). Repligen Corporation's SIR currently stands at 4.58. In other words for every 100,000 Repligen Corporation shares traded daily on the market, roughly 4580 shares are currently held short.
However Repligen Corporation's short interest can also be evaluated against the total number of Repligen Corporation shares, or, against the total number of tradable Repligen Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Repligen Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Repligen Corporation shares in existence, roughly 30 shares are currently held short) or 0.0311% of the tradable shares (for every 100,000 tradable Repligen Corporation shares, roughly 31 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Repligen Corporation.
Find out more about how you can short Repligen Corporation stock.
We're not expecting Repligen Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Repligen Corporation's shares have ranged in value from as little as $138 up to $243.72. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repligen Corporation's is 0.8553. This would suggest that Repligen Corporation's shares are less volatile than average (for this exchange).
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.